Autor: "Nachar VR" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Incidence and risk factors for bacterial infection using bortezomib, lenalidomide, and dexamethasone (RVd) in newly diagnosed multiple myeloma.
Autorzy:: Bici A; Department of Pharmacy Services, Michigan Medicine and the University of Michigan College of Pharmacy, Ann Arbor, MI, USA.
Pianko MJ; Division of Hematology and Oncology, Department of Internal Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
Nachar VR; Department of Pharmacy Services, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.; Pokaż więcej
Źródło:: Leukemia & lymphoma [Leuk Lymphoma] 2023 Feb; Vol. 64 (2), pp. 407-414. Date of Electronic Publication: 2022 Oct 29.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Multiple Myeloma*/diagnosis
Multiple Myeloma*/drug therapy
Multiple Myeloma*/epidemiology
Bacterial Infections*/diagnosis
Bacterial Infections*/epidemiology
Bacterial Infections*/etiology
Humans ; Infant ; Lenalidomide/adverse effects ; Bortezomib/adverse effects ; Incidence ; Retrospective Studies ; Cohort Studies ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Risk Factors ; Dexamethasone/adverse effects

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Late-onset complications with bendamustine versus CHOP or CVP based chemoimmunotherapy in indolent Non-Hodgkin's lymphoma.
Autorzy:: Baek GT; Department of Pharmacy Services and Clinical Pharmacy, Michigan Medicine, Ann Arbor, MI, USA.
Mathis NJ; Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Perissinotti AJ; Department of Pharmacy Services and Clinical Pharmacy, Michigan Medicine, Ann Arbor, MI, USA.; College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Marini BL; Department of Pharmacy Services and Clinical Pharmacy, Michigan Medicine, Ann Arbor, MI, USA.; College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Brown A; Department of Pharmacy Services and Clinical Pharmacy, Michigan Medicine, Ann Arbor, MI, USA.; College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Phillips TJ; Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA.
Wilcox RA; Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA.
Nachar VR; Department of Pharmacy Services and Clinical Pharmacy, Michigan Medicine, Ann Arbor, MI, USA.; College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.; Pokaż więcej
Źródło:: Leukemia & lymphoma [Leuk Lymphoma] 2021 Dec; Vol. 62 (13), pp. 3138-3146. Date of Electronic Publication: 2021 Jul 15.
Typ publikacji:: Journal Article
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Lymphoma, Non-Hodgkin*/drug therapy
Adult ; Bendamustine Hydrochloride/adverse effects ; Cyclophosphamide/adverse effects ; Humans ; Retrospective Studies ; Rituximab/adverse effects

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Impact of a vincristine dose cap on the incidence of neuropathies with DA-EPOCH-R for the treatment of aggressive lymphomas.
Autorzy:: Weis TM; Department of Pharmacy Services and Clinical Sciences, Michigan Medicine and University of Michigan College of Pharmacy, Ann Arbor, MI, USA.
Marini BL; Department of Pharmacy Services and Clinical Sciences, Michigan Medicine and University of Michigan College of Pharmacy, Ann Arbor, MI, USA.
Nachar VR; Department of Pharmacy Services and Clinical Sciences, Michigan Medicine and University of Michigan College of Pharmacy, Ann Arbor, MI, USA.
Brown AM; Department of Pharmacy Services and Clinical Sciences, Michigan Medicine and University of Michigan College of Pharmacy, Ann Arbor, MI, USA.
Phillips TJ; Department of Internal Medicine, Division of Hematology and Oncology, Michigan Medicine and University of Michigan Medical School, Ann Arbor, MI, USA.
Brown J; Department of Pharmacy Services and Clinical Sciences, Michigan Medicine and University of Michigan College of Pharmacy, Ann Arbor, MI, USA.
Wilcox RA; Department of Internal Medicine, Division of Hematology and Oncology, Michigan Medicine and University of Michigan Medical School, Ann Arbor, MI, USA.
Kaminski MS; Department of Internal Medicine, Division of Hematology and Oncology, Michigan Medicine and University of Michigan Medical School, Ann Arbor, MI, USA.
Devata S; Department of Internal Medicine, Division of Hematology and Oncology, Michigan Medicine and University of Michigan Medical School, Ann Arbor, MI, USA.
Perissinotti AJ; Department of Pharmacy Services and Clinical Sciences, Michigan Medicine and University of Michigan College of Pharmacy, Ann Arbor, MI, USA.; Pokaż więcej
Źródło:: Leukemia & lymphoma [Leuk Lymphoma] 2020 May; Vol. 61 (5), pp. 1126-1132. Date of Electronic Publication: 2019 Dec 26.
Typ publikacji:: Journal Article
MeSH Terms:: Lymphoma, Large B-Cell, Diffuse*/drug therapy
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Cyclophosphamide/therapeutic use ; Doxorubicin/therapeutic use ; Etoposide/therapeutic use ; Humans ; Incidence ; Prednisone/therapeutic use ; Retrospective Studies ; Rituximab/therapeutic use ; Vincristine/adverse effects
SCR Protocol:: EPOCH protocol

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma.
Autorzy:: Hoylman E; Department of Pharmacy Services and Clinical Sciences, Michigan Medicine, University of Michigan College of Pharmacy, Ann Arbor, MI, USA.
Brown A; Department of Pharmacy Services and Clinical Sciences, Michigan Medicine, University of Michigan College of Pharmacy, Ann Arbor, MI, USA.
Perissinotti AJ; Department of Pharmacy Services and Clinical Sciences, Michigan Medicine, University of Michigan College of Pharmacy, Ann Arbor, MI, USA.
Marini BL; Department of Pharmacy Services and Clinical Sciences, Michigan Medicine, University of Michigan College of Pharmacy, Ann Arbor, MI, USA.
Pianko M; Department of Internal Medicine, Division of Hematology and Oncology, Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA.
Ye JC; Department of Internal Medicine, Division of Hematology and Oncology, Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA.
Campagnaro E; Department of Internal Medicine, Division of Hematology and Oncology, Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA.
Nachar VR; Department of Pharmacy Services and Clinical Sciences, Michigan Medicine, University of Michigan College of Pharmacy, Ann Arbor, MI, USA.; Pokaż więcej
Źródło:: Leukemia & lymphoma [Leuk Lymphoma] 2020 Mar; Vol. 61 (3), pp. 691-698. Date of Electronic Publication: 2019 Nov 18.
Typ publikacji:: Journal Article
MeSH Terms:: Multiple Myeloma*/drug therapy
Antibodies, Monoclonal/*therapeutic use
Antibodies, Monoclonal, Humanized/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Nachar VR"" wg kryterium: Autor

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Język